ArticleAAPS PharmSciTech2023
Article in AAPS PharmSciTech, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Nano-antimicrobial peptides (Nano-AMPs) to combat resistant gram-negative bacteria.Drug delivery and translational research · 2026Review
- Ethosomal Gel-Based Topical Delivery of Albendazole Hydrochloride for Psoriasis: In Vitro and In Vivo Evaluation.AAPS PharmSciTech · 2026Article
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
- Liposome-Encapsulated Antibiotics for the Therapy of Mycobacterial Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Radiolabeling of bionanomaterials with technetium 99m: current state and future prospects.Nanomedicine (London, England) · 2024Review
- Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders.ACS omega · 2023Article
- Innovative Phospholipid Carriers: A Viable Strategy to Counteract Antimicrobial Resistance.International journal of molecular sciences · 2023Review
- Radiological and Imaging Evidence in the Diagnosis and Management of Microbial Infections: An Update.Cureus · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Infectious diseases are still the major issue not only due to antibiotic resistance but also causing deaths if not diagnosed at early-stages. Different approaches including nanosized drug delivery systems and theranostics are researched to overcome antibiotic resistance, decrease the side effects of antibiotics, improve the treatment response, and early diagnose. Therefore, in the present study, nanosized, radiolabeled with
Indexed as
Identifiers
36899198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.